【摘要】 目的　探讨尼莫通预防和治疗蛛网膜下腔出血 (SAH)后脑血管痉挛 (CVS)引起的缺血性神经功能障碍的价值。方法　对照组 30例 ,入院后给予 6 -氨基已酸等抗纤溶药降低颅内压力及一般对症治疗。治疗组 6 0例 ,加用尼莫通每日 10mg ,用微量静脉输液泵 ,静脉序贯给药 5～ 10天 ,后口服至 2 1天的治疗方法。结果　 2周内临床症状或体征缓解消失率尼莫通组高于对照组 ,P <0 .0 1,1月后致残、致死率对照组高于尼莫通组 ,P <0 .0 1。结论　尼莫通能降低SAH病人延迟性缺血性神经功能障碍的发生率和病死率 ,尼莫通治疗SAH有明显效果。更多还原

【Abstract】 Objectives To explore the value of Nimotop on prevention and cure ischemi obstacle by CVS following experimental SAH.Methods 30 samples were treated with 6-amino acetic acid to decrease encephalic pressure and normal cure as a control. 60 samples were treated with additional Nimotop at the level of 10mg/d through micro-quantity vein pump for 5 to 10 days, then took orally until 21 days. Results Within two weeks, the clinical symptoms is reduced, the disappearing ratio on Nimotop group is higher significantly (P<0.01) than that in control.The ratio of deformity and mortality in control is higher significantly (P<0.01) than Nimotop group after one month. Conclusions Nimotop can decrease appearance and mortality ratio of SAH patients sufferiny from ischemic nerous function obstacle. Nimoptop appears significant effect on SAH.更多还原